← Back to all trials
Not Yet Recruiting
NCT05612607
Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies
Conditions: Secondary Antibody Deficiency
Sex: All
Ages: 18 Years – N/A
Phase: PHASE4
Enrollment: 100
Sponsor: Ottawa Hospital Research Institute
Summary
Current treatment for patients with secondary antibody deficiency (SAD) is Immunoglobulin replacement therapy (IGRT).
There are currently no clinical guidelines for IGRT discontinuation in patients with SAD.
This study will examine the IGRT discontinuation success rate and IGRT discontinuation rate in patients.
Eligibility Criteria
Inclusion Criteria:History of leukemia, lymphoma, or plasma cell diseaseReceiving IGRT for SAD for at least 12 monthsOver 18 years of ageAble to provide informed consentAble to speak English or FrenchAvailable for ongoing follow-up as requiredExclusion Criteria:Receiving chemotherapy or immune-oncology treatment during the study periodSevere infection within the last 6 monthsPregnancy
Source: ClinicalTrials.gov (NCT05612607). StuddyBuddy aggregates publicly available trial information.
